- Home
- CVS vs BMY Comparison
CVS vs BMY Comparison
Compare CVS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVS | BMY |
|---|---|---|
| Founded | 1963 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.1B | 115.3B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | CVS | BMY |
|---|---|---|
| Price | $95.93 | $57.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $94.72 | $61.73 |
| AVG Volume (30 Days) | 7.5M | ★ 8.9M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | 3.17% | ★ 4.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $402,067,000,000.00 | N/A |
| Revenue This Year | $2.36 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | $41.10 | ★ $17.26 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $58.50 | $42.52 |
| 52 Week High | $98.43 | $62.89 |
Technical Indicators
Market Signals| Indicator | CVS | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 50.47 |
| Support Level | $73.66 | $56.36 |
| Resistance Level | $98.43 | $60.50 |
| Average True Range (ATR) | 2.05 | 1.40 |
| MACD | -0.43 | -0.08 |
| Stochastic Oscillator | 87.24 | 50.58 |
Price Performance
Historical ComparisonAbout CVS CVS Health Corporation
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.